LACTOLOGY FOUNDATION

Lubiprostone (A06AX03) is an oral secretagogue laxative used for chronic idiopathic constipation, opioid‑induced constipation and IBS‑C, with low systemic bioavailability and an overall low expected risk in breastfeeding, although human lactation data are limited and infant monitoring for diarrhea is advised.atcddd.fhi+8

Pharmacotherapeutic group and mechanism

Lubiprostone is classified in ATC subgroup A06AX “Other drugs for constipation” under code A06AX03.atcddd.fhi+3
It is a prostaglandin E1‑derived bicyclic fatty acid that selectively activates ClC‑2 chloride channels on the apical surface of intestinal epithelial cells, promoting secretion of chloride‑rich fluid into the lumen; this softens stool, increases intestinal motility and leads to more frequent spontaneous bowel movements.drugbank+3

Indications, dosage and administration

Lubiprostone is indicated for adult patients with chronic idiopathic constipation, opioid‑induced constipation in chronic non‑cancer pain (and certain long‑lasting cancer‑related pain) and irritable bowel syndrome with constipation (IBS‑C) in women aged 18 years and older.mayoclinic+4
Typical oral dosing for chronic idiopathic constipation and opioid‑induced constipation is 24 micrograms twice daily with food and water, and for IBS‑C, 8 micrograms twice daily; capsules are soft gelatin formulations that must be swallowed whole without crushing or chewing.webmd+2
Lubiprostone has low systemic availability after oral administration, reflecting its predominantly local intestinal action; the ATC/DDD Index lists A06AX03 as lubiprostone within “other drugs for constipation” but does not specify a DDD value in the brief listing.atcddd.fhi+2

General toxicological profile

Because lubiprostone acts by increasing intestinal fluid secretion, its main adverse effects are gastrointestinal: nausea, diarrhea, abdominal pain, distension, flatulence and a sensation of fullness or bloating.clevelandclinic+2
Nausea is dose‑related and often mitigated by taking the capsule with food and water; severe diarrhea may lead to dehydration or electrolyte disturbances, and labeling recommends dose adjustment or discontinuation if clinically significant diarrhea occurs.mayoclinic+1

Non‑gastrointestinal adverse reactions include headache and, less frequently, dyspnea or chest tightness, which are typically transient; lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction because its secretory mechanism can worsen obstructive symptoms.accessdata.fda+2

Preclinical studies and post‑marketing data have not demonstrated major systemic organ toxicity at therapeutic doses, consistent with its low systemic exposure. However, as with any prostaglandin‑related agent, caution is recommended in patients with severe comorbidities, and therapy should follow standard prescribing information.

Lactation‑toxicology considerations

Product labeling states that it is not known whether lubiprostone is excreted in human breast milk, so a cautious approach is recommended.webmd+1
Animal data indicate that neither lubiprostone nor its active metabolites were detectable in the breast milk of rats following oral administration; manufacturers and secondary references report undetectable levels in rat milk and conclude that lubiprostone would not be expected to cause adverse effects in breastfed infants.drugs+2

Based on these findings and the drug’s low systemic bioavailability, lactation experts consider lubiprostone unlikely to pose significant risk to breastfed infants, but they advise monitoring for diarrhea or changes in stool consistency if the mother is treated. Lubiprostone’s mechanism—local chloride channel activation—means any theoretical infant exposure via milk would act in the gut; if present at meaningful levels, it could potentially increase intestinal fluid and cause loose stools, although current evidence suggests such exposure is very small.drugs+1

General guidance on laxatives in breastfeeding indicates that most laxatives are either not absorbed or only minimally absorbed from the maternal gastrointestinal tract, leading to low or negligible levels in breast milk, and that they can usually be used during breastfeeding as long as infant monitoring is appropriate for agents with systemic activity. Lubiprostone fits within this paradigm as a predominantly locally acting secretagogue with supporting animal data for minimal milk transfer, justifying its consideration when first‑line laxatives are insufficient.sps+1

Clinical use in breastfeeding women

In breastfeeding women, constipation management should prioritize lifestyle modifications and laxatives with extensive lactation safety experience (bulk‑forming and osmotic agents), but lubiprostone can be considered when chronic idiopathic constipation, IBS‑C or opioid‑induced constipation remains refractory.sps+3
When lubiprostone is prescribed to a nursing mother, clinicians should use standard adult doses, ensure the medicine is taken with food and adequate fluid to reduce nausea, and inform the mother to observe the infant for diarrhea, changes in stool frequency or feeding difficulties, although clinically significant infant effects are not expected based on current evidence.drugs+3

Decisions about continuing lubiprostone or breastfeeding should weigh maternal benefits (relief of chronic constipation, improved quality of life and analgesia adherence) against the theoretical, but likely low, infant risk; in most cases, ongoing breastfeeding with infant monitoring is reasonable, rather than routine interruption. Documentation of indication, dose, treatment duration and infant outcomes is advisable to contribute to clinical experience in this area.